The Top 3 Biotech Stocks to Consider in 2020

It's tough to discount the bullish case for biotech and pharmaceutical stocks.

For one, millions of retiring baby boomers not only exploring new ways to shave off signs of aging, they are looking to postpone health-related decline and even death.

In addition, we're seeing countless mergers and acquisitions.

We're also seeing new, innovative treatments for a myriad of issues, including cancer.

And if you're in the right place at the right time, the windfall profits are endless.

Because – let's face it – making money from this solid, unbreakable sector couldn't be any easier. Plus, with heavy demand, and exciting new innovation, biotech stocks are some of the most exciting trades on market – not to mention recession-proof.

Top Biotech Stock No. 1 – Fate Therapeutics (FATE)

Fate Therapeutics (FATE) has seen an incredible amount of momentum.

The stock could see further big interest on news the U.S. FDA cleared the company's Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.

“FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy,” says the company.

From here, the company plans to a clinical investigation of FT819 for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

Top Biotech Stock No. 2 – Trillium Therapeutics (TRIL)

Shares of TRIL may have already rocketed from a low of 30 cents to $7.25.
But the run may have only just begun thanks to progress on potential cancer treatments, including an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma.

“The data emerging from this dose escalation study suggest that TTI-622 is a promising and highly differentiated CD47 blocker,” said Jan Skvarka, President and Chief Executive Officer of Trillium. “We are seeing strong tolerability, consistent with the red blood cell-sparing property associated with this molecule. Both drug exposure and target engagement have shown dose response relationships. Notably, in addition to the previously reported monotherapy complete response, we have observed a partial response in a second DLBCL patient.”

Top Biotech Stock No. 3 – CytoDyn Inc. (CYDY)

CYDY is a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. CYDY has been pushing higher on virus and NASH news.

With NASH, the company just initiated Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2 trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.

“There are currently no U.S. Food and Drug Administration (FDA) approved treatments for NASH and it is expected to be the number one cause of liver transplant by 2020. About 30 to 40 percent of adults in the U.S. are living with NAFLD, and 3 to 12 percent of adults in the U.S. are living with NASH,” says the company.